Novo Nordisk

The agreement comes as Novo continues to strengthen its position in cardiometabolic medicines, where longer dosing intervals are a growing focus of research and development.

The FDA approval was supported by findings from the Phase 3a ONWARDS clinical program, which evaluated once-weekly Awiqli® in adults with type 2 diabetes.

Novo Nordisk will also use H1’s technology to support several aspects of clinical research, including trial design, patient enrollment and clinical trial site selection.

Kalyan brings nearly 30 years of experience in the pharmaceutical and healthcare industries, including 18 years with Novo Nordisk.

Under the agreement, Novo Nordisk will internally assess Vivani’s investigational NPM-139 implant, which utilizes the company’s proprietary NanoPortal technology to deliver semaglutide continuously over extended periods through a miniature subdermal device.

Novo Nordisk invested 3.5 billion Czech koruna (US$168 million) in modernisation works following its US$200 million acquisition of the facility.

Under the new agreement, EDE and Novo Nordisk will work together to enhance pharmaceutical supply chain security by increasing in-country value creation and expanding strategic partnerships that help maintain a steady supply of medicines.

Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management.

Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.